# High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients

> **NCT03179761** · PHASE2 · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 124 (actual)

## Conditions studied

- Hematopoietic Cell Transplantation

## Interventions

- **BIOLOGICAL:** Quadrivalent Inactivated Influenza Vaccine
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Trivalent Influenza Vaccine

## Key facts

- **NCT ID:** NCT03179761
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-09
- **Primary completion:** 2022-02-15
- **Final completion:** 2024-10-01
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03179761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03179761, "High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03179761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*